Evaluation of In-Vitro Activity of Ceftaroline Against Methicillin-Resistant Staphylococcus aureus Clinical Isolates.

Autor:	Roy A; Microbiology, Kalinga Institute of Medical Sciences, Bhubaneswar, IND., Poddar N; Microbiology, Kalinga Institute of Medical Sciences, Bhubaneswar, IND., Panigrahi K; Microbiology, Kalinga Institute of Medical Sciences, Bhubaneswar, IND., Pathi B; Microbiology, Kalinga Institute of Medical Sciences, Bhubaneswar, IND., Nayak SR; Microbiology, Kalinga Institute of Medical Sciences, Bhubaneswar, IND., Dandapat R; Microbiology, Kalinga Institute of Medical Sciences, Bhubaneswar, IND., Pattnaik D; Microbiology, Kalinga Institute of Medical Sciences, Bhubaneswar, IND., Praharaj AK; Microbiology, Kalinga Institute of Medical Sciences, Bhubaneswar, IND., Patro ARK; Microbiology, Kalinga Institute of Medical Sciences, Bhubaneswar, IND.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Dec 03; Vol. 15 (12), pp. e49859. Date of Electronic Publication: 2023 Dec 03 (Print Publication: 2023).
DOI:	10.7759/cureus.49859
Abstrakt:	Methicillin-resistant Staphylococcus aureus (MRSA) is one of the major causes of hospital and community-acquired infections. Fewer drugs, such as vancomycin, teicoplanin, and daptomycin, are effective against it, but they come with high toxicity. Fifth-generation cephalosporins like ceftaroline and second-generation cefuroxime are effective against MRSA. Limited studies are available on ceftaroline resistance in the literature. This study was undertaken to determine ceftaroline resistance in MRSA in a tertiary care hospital in Eastern India. A cross-sectional, hospital-based study was carried out with MRSA isolates obtained from various clinical samples of patients. Identification of the isolates to the species level was performed by an automated Vitek system, and selected samples were genotypically confirmed by detecting the mecA gene via real-time PCR. Out of a total of 334 Staphylococcus aureus isolates examined in this study, the prevalence of MRSA was seen in 59.3% (198/334), and methicillin-sensitive Staphylococcus aureus was in 40.7% (136/334). Of the total 198 MRSA isolates, ceftaroline intermediate MRSA was seen in 8.6% (17/198), and ceftaroline sensitive MRSA was in 91.4% (181/198), respectively. Among the 17 ceftaroline intermediate MRSA isolates, 88.2% (15/17) showed a minimum inhibitory concentration (MIC) of 2 µg/ml, and 11.8% (2/17) showed an MIC of 3 µg/ml. All the remaining 91.4% (181/198) isolates were sensitive to ceftaroline and showed an MIC ≤1 µg/ml. Real-time PCR confirmed the presence of the mecA gene in MRSA isolates. In this present study, not a single isolate was resistant to ceftaroline, suggesting that it, being a safer drug, can be used in place of glycopeptides such as vancomycin or teicoplanin and linezolid, where resistance has already been detected. The rational use of ceftaroline could be useful in clinical settings, and further studies will confirm the findings. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Roy et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu